incremental tax benefit in 2007 and 2006, respectively, for the pre-
tax reconciling items between GAAP and adjusted net income; ii) in
2007, $31.9 of incremental tax benefit from adjusting the company's
deferred tax balances as a result of newly enacted tax rates in the
United Kingdom, Denmark, Germany and Canada; and iii) in
2006, $1.2 of incremental tax provision for the estimated effect of
tax audits of prior years in a non-U.S. country.
(i) Consolidated depreciation expense in 2007 and 2006 is $185.7 and
(j) Consolidated equity compensation expense included in both reported and
adjusted results is $51.1 and $32.6 in 2007 and 2006, respectively,
aside from the 2006 charge discussed in note (e).
(k) Pro forma results combine the results of the company with the pre-
merger results of Fisher Scientific International Inc. Equity
compensation expense of $74.7 is included in the pro forma 2006
Note: Consolidated net capital expenditures in 2007 totaled $156.3.
Condensed Consolidated Balance Sheet
(In millions) Dec. 31, 2007 Dec. 31, 2006
Cash and cash equivalents $636.2 $667.4
Short-term investments 14.1 23.8
Accounts receivable, net 1,450.0 1,392.7
Inventories 1,169.9 1,164.5
Other current assets 408.9 411.1
Total current assets 3,679.1 3,659.5
Property, Plant and Equipment, Net 1,267.4 1,256.7
Acquisition-related Intangible Assets 7,157.8 7,511.6
|SOURCE Thermo Fisher Scientific Inc.|
Copyright©2008 PR Newswire.
All rights reserved